Compare AstraZeneca plc (AZN) vs Sezzle Inc (SEZL) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

SEZL trades at $160.25, down 10.66% over the last session, but maintains a bullish technical outlook with support at $156 and resistance at $165. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.43, and raised full-year guidance. Revenue growth accelerated to 29% year-over-year, with net income margin expanding to 30.83%.

Outlook remains positive given consistent earnings beats and product expansion, though high valuation multiples (P/E 43.68) and a recent securities law investigation pose risks. Analyst consensus is split evenly between Buy and Hold, with a $162 price target suggesting modest upside from current levels.